Lester RM, Paglialunga S, Johnson IA. QT assessment in early drug development: the long and the short of it. Int J Mol Sci. 2019;20(6):1324.
Article CAS PubMed PubMed Central Google Scholar
Fernandes FM, Silva EP, Martins RR, Oliveira AG. QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. PLoS One. 2018;13(6):e0199028.
Article PubMed PubMed Central Google Scholar
Tisdale JE, Wroblewski HA, Overholser BR, et al. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf. 2012;35(6):459–70.
Article CAS PubMed Google Scholar
Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care. 2013;28(3):243–9.
Hoogstraaten E, Rijkenberg S, van der Voort PH. Corrected QT-interval prolongation and variability in intensive care patients. J Crit Care. 2014;29(5):835–9.
Fernandes FM, da Silva Paulino AM, Sedda BC, et al. Assessment of the risk of QT-interval prolongation associated with potential drug-drug interactions in patients admitted to Intensive Care Units. Saudi Pharm J. 2019;27(2):229–34.
QT Drugs Lists. 2022. https://crediblemeds.org/druglist. Accessed 26 May 2022.
Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut and liver. 2017;11(1):27–37.
Article CAS PubMed Google Scholar
Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton pump inhibitors: review of emerging concerns. Mayo Clinic Proc. 2018;93(2):240–6.
Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9(3):132–9.
Article CAS PubMed Google Scholar
Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11(11):1123–34.
Article CAS PubMed Google Scholar
Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4):553–6.
Article CAS PubMed Google Scholar
Lazzerini PE, Bertolozzi I, Finizola F, et al. Proton pump inhibitors and serum magnesium levels in patients with torsades de pointes. Front Pharmacol. 2018;9:363.
Article PubMed PubMed Central Google Scholar
Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405–13.
Article CAS PubMed Google Scholar
Bibawy JN, Parikh V, Wahba J, et al. Pantoprazole (proton pump inhibitor) contributing to torsades de Pointes storm. Circ Arrhythm Electrophysiol. 2013;6(2):e17–9.
Lazzerini PE, Cartocci A, Qu YS, et al. Proton pump inhibitors directly block hERG-potassium channel and independently increase the risk of QTc prolongation in a large cohort of US veterans. Circ Arrhythm Electrophysiol. 2021;14(7):e010042.
Article CAS PubMed Google Scholar
Rooney MR, Bell EJ, Alonso A, et al. Proton pump inhibitor use, hypomagnesemia and risk of cardiovascular diseases: the atherosclerosis risk in communities (ARIC) study. J Clin Gastroenterol. 2021;55(8):677–83.
Article CAS PubMed PubMed Central Google Scholar
Toews I, George AT, Peter JV, et al. Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units. Cochrane Database Syst Rev. 2018;6(6):CD008687. https://doi.org/10.1002/14651858.CD008687.pub2
Johnson AE, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3:160035.
Article CAS PubMed PubMed Central Google Scholar
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
Article PubMed PubMed Central Google Scholar
George TK, Chase D, Peter JV, et al. Association between a prolonged corrected QT interval and outcomes in patients in a medical Intensive Care Unit. Indian J Crit Care Med. 2015;19(6):326–32.
Article PubMed PubMed Central Google Scholar
Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047–60.
Article PubMed PubMed Central Google Scholar
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–22.
Article CAS PubMed Google Scholar
Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol. 2016;67(13):1639–50.
El-Charabaty E, Saifan C, Abdallah M, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med. 2013;6:515–8.
PubMed PubMed Central Google Scholar
Lorberbaum T, Sampson KJ, Chang JB, et al. Coupling data mining and laboratory experiments to discover drug interactions causing QT prolongation. J Am Coll Cardiol. 2016;68(16):1756–64.
Article CAS PubMed PubMed Central Google Scholar
Tasci O, Kiran TE. Does the use of proton pump inhibitors in children affect ventricular repolarisation parameters? Cardiol Young. 2022;2:1–5.
Wolfes J, Ellermann C, Burde S, et al. Concomitant treatment with proton pump inhibitors and cephalosporins does not enhance QT-associated proarrhythmia in isolated rabbit hearts. Cardiovasc Toxicol. 2020;20(6):531–8.
Article CAS PubMed Google Scholar
Malihi G, Nikoui V, Elson EL. A review on qualifications and cost effectiveness of induced pluripotent stem cells (IPSCs)-induced cardiomyocytes in drug screening tests. Arch Physiol Biochem. 2020;1–12.
Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122–6.
Article CAS PubMed Google Scholar
Guo J, Zhan S, Lees-Miller JP, Teng G, Duff HJ. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. Heart Rhythm. 2005;2(8):860–6.
Teschemacher AG, Seward EP, Hancox JC, Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol. 1999;128(2):479–85.
Article CAS PubMed PubMed Central Google Scholar
Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774–82.
Article CAS PubMed Google Scholar
Zünkler BJ, Wos-Maganga M. Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels. Cardiovasc Toxicol. 2010;10(3):161–5.
Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2000;295(2):614–20.
Claassen S, Zünkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005;74(1):31–6.
Article CAS PubMed Google Scholar
Asajima H, Saito N, Ohmura Y, Ohmura K. Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide. Eur J Clin Pharmacol. 2012;68(3):331–3.
Assimon MM, Pun PH, Al-Khatib SM, et al. Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. Pharmacoepidemiol Drug Saf. 2022;31(6):670–9.
Article PubMed PubMed Central Google Scholar
Khan Q, Ismail M, Haider I, Ali Z. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients. J Formos Med Assoc. 2019;118:109–15.
Ye Z, Reintam Blaser A, Lytvyn L, et al. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ. 2020;368:l6722.
留言 (0)